Additionally, BEZ235 (Dactolisib), a dual PI3K/mTOR inhibitor, has shown antitumor activity in preclinical models of HCC by targeting the PI3K/AKT/mTOR pathway, reducing tumor cell proliferation and inducing apoptosis (Oh et al., 2016). This evidence concerns the gene AKT1 and hepatocellular carcinoma.